Photo: Teva

19 May 2014Americas

US court denies Teva’s final shot at blocking Copaxone copies

A US district court has dismissed Teva’s case against the US Food and Drug Administration (FDA) aimed at stopping the administration from approving generic versions of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

'This is a big problem’: The CRISPR controversy and the ‘mess’ at the heart of the EPO’s appeals boards

‘I’m breaking new ground’: Mölnlycke’s first TM attorney charts a new course

Drug approvals up but global innovation declines

‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute

Preventative IP for preventative pharma healthcare

Court denies Regeneron bid to halt copy of blockbuster eye drug

Interview: Klaus Grabinski, UPC Court of Appeal president

Gilead scores win in fake HIV drug dispute